Mosaic ImmunoEngineering (CPMV) Share-based Compensation (2010 - 2024)
Mosaic ImmunoEngineering (CPMV) posted quarterly Share-based Compensation of $4867.0 for Q1 2024, down 10.0% year-over-year from $5408.0 in Q2 2023, and down 11.97% quarter-over-quarter from $5529.0 in Q4 2023.
Mosaic ImmunoEngineering (CPMV) Share-based Compensation (2010 - 2024) Analysis & Trends
Mosaic ImmunoEngineering's Share-based Compensation history runs 8 years deep, the most recent figure standing at $4867.0 for Q1 2024.
- In Q1 2024, Share-based Compensation fell 10.0% year-over-year to $4867.0; the TTM figure through Dec 2024 stood at $4867.0 (down 77.81% YoY), while the FY2024 annual figure was $4867.0, down 77.81% from the prior year.
- Share-based Compensation for Q1 2024 stood at $4867.0, down from $5529.0 in the prior quarter.
- The five-year high for Share-based Compensation was $420779.0 in Q2 2021, with the low at $4867.0 in Q1 2024.
- The 4-year median for Share-based Compensation is $51592.0 (2022), against an average of $125379.5.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation tumbled 97.42% in 2022, then declined 10.0% in 2024.
- Mosaic ImmunoEngineering's Share-based Compensation stood at $253001.0 in 2021, then sank by 97.42% to $6529.0 in 2022, then declined by 15.32% to $5529.0 in 2023, then retreated by 11.97% to $4867.0 in 2024.
- Business Quant data shows CPMV's Share-based Compensation at $4867.0 in Q1 2024, $5529.0 in Q4 2023, and $5529.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 4,867.00 |
| Mar 31, 2024 | 4,867.00 |
| Dec 31, 2023 | 5,529.00 |
| Dec 31, 2023 | 5,529.00 |
| Sep 30, 2023 | 5,529.00 |
| Sep 30, 2023 | 5,529.00 |
| Jun 30, 2023 | 5,469.00 |
| Jun 30, 2023 | 5,469.00 |
| Mar 31, 2023 | 5,408.00 |
| Mar 31, 2023 | 5,408.00 |
| Dec 31, 2022 | 6,529.00 |
| Dec 31, 2022 | 6,529.00 |
| Sep 30, 2022 | 51,592.00 |
| Sep 30, 2022 | 51,592.00 |
| Jun 30, 2022 | 97,997.00 |
| Jun 30, 2022 | 97,997.00 |
| Mar 31, 2022 | 139,005.00 |
| Mar 31, 2022 | 139,005.00 |
| Dec 31, 2021 | 253,001.00 |
| Dec 31, 2021 | 253,001.00 |